Addbiotech Acquires 10 Billion Won Stake in Onheal to Secure Future Growth Engines View original image

Addbiotech, a bio company specializing in immunoantibodies, has invested approximately 10 billion won in Onheal, a pet healthcare company, to secure future growth engines.


Addbiotech announced on July 6 that its board of directors had resolved on July 3 to acquire 181,269 shares of Onheal. The acquisition amount is 9,969,790,000 won, which accounts for 29.25% of the company’s equity capital. Once the transaction is completed, Addbiotech’s stake in Onheal will be 12.28%, making it the second-largest shareholder after CEO Kim Dohyung of Addbiotech.


The company explained that this investment is a strategic move to diversify its business portfolio and secure future growth engines. Backed by a stable financial base and the prompt execution of the investment, Addbiotech expects full-fledged business synergies between the two companies going forward.


Since appointing CEO Kim Dohyung at an extraordinary general meeting of shareholders in June, Addbiotech has strengthened the competitiveness of its existing immunoantibody business while expanding its operations into future bioindustries such as bio research and development (R&D), medical and healthcare, pet care, and digital platforms.


Onheal is a company engaged in non-clinical clinical trial consignment organization (CRO) business, pharmaceutical and medical device design and distribution, veterinary drug licensing, the VETUS animal hospital prescription platform, business-to-consumer (B2C) distribution for pet owners, and pet healthcare research and development, all based on the concept of One Health.



An Addbiotech official stated, “This equity acquisition is part of our business diversification strategy for sustainable growth,” adding, “We plan to strengthen our strategic partnership with Onheal based on our acquired stake and actively seek out new business opportunities.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing